$7.63
3.78% today
Nasdaq, Apr 01, 07:20 pm CET
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Day One Biopharmaceuticals Inc Stock price

$7.93
-1.13 12.47% 1M
-6.00 43.07% 6M
-4.74 37.41% YTD
-8.23 50.93% 1Y
-1.99 20.06% 3Y
+6.88 655.24% 5Y
+6.88 655.24% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.14 1.73%
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Key metrics

Market capitalization $803.75m
Enterprise Value $274.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.09
P/S ratio (TTM) P/S ratio 6.13
P/B ratio (TTM) P/B ratio 1.59
Revenue (TTM) Revenue $131.16m
EBIT (operating result TTM) EBIT $-217.27m
Free Cash Flow (TTM) Free Cash Flow $-80.28m
Cash position $531.72m
EPS (TTM) EPS $-1.04
P/E forward negative
P/S forward 4.93
EV/Sales forward 1.69
Short interest 20.27%
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
131 131
-
100%
- Direct Costs 5.40 5.40
1,321% 1,321%
4%
126 126
33,197% 33,197%
96%
- Selling and Administrative Expenses 113 113
52% 52%
86%
- Research and Development Expense 228 228
74% 74%
174%
-215 -215
5% 5%
-164%
- Depreciation and Amortization 2.03 2.03
434% 434%
2%
EBIT (Operating Income) EBIT -217 -217
5% 5%
-166%
Net Profit -96 -96
49% 49%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Neutral
Seeking Alpha
about one month ago
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldon...
Neutral
GlobeNewsWire
about one month ago
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively
Neutral
GlobeNewsWire
about 2 months ago
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m.
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 181
Founded 2018
Website www.dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today